New research suggest that Donanemab, a investigational drug, may slow the advance of early-stage cognitive decline. This therapy works by clearing amyloid plaques within the central nervous https://gorillasocialwork.com/story26750689/nadecenemab-an-emerging-new-cognitive-approach